Correction – altimmune presents results of a phase 2 mri-based body composition sub-study at 60th annual meeting of the european association for the study of diabetes

Gaithersburg, md., sept. 10, 2024 (globe newswire) -- in a release issued under the same headline earlier today by altimmune, inc. (nasdaq:alt), please note that the reduction of visceral adipose tissue (vat) at week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. the revised release follows:
ALT Ratings Summary
ALT Quant Ranking